COMMUNIQUÉS West-GlobeNewswire

Herz P1 Smart BPM Under Investigation: Clinical-Grade Blood Pressure Monitoring for Valuable At-Home Health Tracking Support
20/04/2026
A 2026 informational overview of Herz P1 Smart BPM FDA 510K clearance, wrist blood pressure monitor accuracy considerations, irregular heartbeat detection features, at-home cardiovascular tracking awareness, and key [...]
FLYTE EMERGES AS DIRECT BENEFICIARY AS RISING FUEL COSTS DRIVE AIRLINE RETREAT FROM SHORT-HAUL ROUTES
20/04/2026
Major Carriers Accelerate Route Cuts as Economics Break Down, Creating Multi-Billion-Dollar Opportunity in Regional Air Mobility Flyte Expands Focus on High-Frequency Short-Haul Routes to Capture Surging Demand as [...]
IBA – ACQUISITION D’ACTIONS PROPRES
20/04/2026
Louvain-la-Neuve, Belgique, 20 avril 2026 – 21h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
20/04/2026
PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS Masitinib treatment [...]
ViewsML Secures Funding to Accelerate Commercialization of AI-Driven Virtual Biomarker Staining Platform
20/04/2026
VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- ViewsML , a company building the computational layer for biomarker discovery by transforming tissue analysis from a lab process into software, today [...]
Lirum Therapeutics Announces Positive LX-101 Data Selected for Presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting
20/04/2026
New York, NY, April 20, 2026 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that new LX- [...]
GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)
20/04/2026
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 20, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life- [...]
Une analyse médico-économique, la première du genre, montre que le recours précoce à des tests de diagnostic rapides pour soigner le sepsis pourrait sauver des milliers de vies au Canada et réduire les coûts du système de santé dans les pays du G7
20/04/2026
Chaque année, 42 000 Canadiens sont hospitalisés pour des infections sanguines. De nouvelles études montrent que des diagnostics rapides pourraient éviter que 2 400 de ces patients ne développent un sepsis chaque année [...]
BVI Announces CE Mark Under EU MDR for Virtuoso®, A Brand New Dual-Function Surgical Platform
20/04/2026
CE Mark under the European Union Medical Device Regulation (EU MDR) achieved for Virtuoso®, BVI’s first dual-function phaco-vitrectomy platform designed to deliver advanced control, efficiency, and versatility for both [...]
ONWARD Medical Publishes Closing of Bookbuild Offering
20/04/2026
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, April 20, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. ( [...]
First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives in Canada and Reduce Health System Costs Across G7 Countries
20/04/2026
42,000 Canadians are hospitalized with bloodstream infections each year. New findings show fast diagnostics could prevent 2,400 of those patients annually from progressing to sepsis and save $42M for the Canadian [...]
GENFIT : Publication du rapport de performance extra-financière 2026 (exercice 2025)
20/04/2026
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 20 avril 2026 – GENFIT (Euronext : GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies [...]
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
20/04/2026
Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors rarely acquire the [...]
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
20/04/2026
Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults. Clear dose-dependent and [...]
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
20/04/2026
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in [...]
Avicanna Announces Agenda for 6th Annual Clinical Symposium on Cannabinoid Therapeutics
20/04/2026
An established forum for evidence-based clinical discussion, interdisciplinary dialogue, and patient considerations Event is expanded to two days, live and virtual on June 11-12, 2026, at the MaRS Discovery District, [...]
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
20/04/2026
• Enrollment underway at Mackay Base Hospital in Queensland, Australia; additional sites in final activation stages SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical- [...]
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
20/04/2026
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance [...]
Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
20/04/2026
ORION CORPORATION PRESS RELEASE 20 APRIL 2026 at 16.00 EEST Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA Orion Corporation (Orion Pharma) today announced that its investigational [...]

Pages